Cytokinetics, Incorporated develops and commercializes muscle-directed cardiovascular medicines, led by MYQORZO® (aficamten), a cardiac myosin inhibitor approved in the U.S., Europe and China for adults with symptomatic obstructive hypertrophic cardiomyopathy. Company news regularly covers MYQORZO clinical data, launch activity, regulatory approvals and analyses from HCM studies including SEQUOIA-HCM, MAPLE-HCM, FOREST-HCM and ACACIA-HCM.
Recurring updates also address Cytokinetics’ pipeline in cardiac muscle dysfunction, including omecamtiv mecarbil for heart failure with severely reduced ejection fraction and ulacamten for heart failure with preserved ejection fraction. Financial releases and corporate announcements include product revenue, operating updates, shareholder voting matters, common stock offerings and other capital-structure developments.
Cytokinetics (NASDAQ: CYTK) has announced plans to offer $550.0 million in convertible senior notes due 2031 through a private placement to qualified institutional buyers. The company will also grant initial purchasers an option for an additional $82.5 million in notes.
The notes will be senior, unsecured obligations with semi-annual interest payments. Cytokinetics plans to use the proceeds to support the commercial launch of aficamten, expand its development program, advance its research pipeline, and for general corporate purposes. Additionally, the company intends to exchange a portion of its existing 3.50% convertible senior notes due 2027 through privately negotiated transactions.
The notes will be convertible under certain conditions, with settlements made in cash, common stock, or a combination of both, at Cytokinetics' discretion.Cytokinetics (NASDAQ:CYTK) presented new data for aficamten at ESC Congress 2025, strengthening its position as a potential treatment for obstructive hypertrophic cardiomyopathy (oHCM). Key findings from the MAPLE-HCM study showed aficamten's superiority over metoprolol in improving cardiac structure and function.
The data revealed that aficamten demonstrated a low annual incidence rate of atrial fibrillation at 1.5%, consistent with expected rates in HCM patients. Long-term safety data from FOREST-HCM showed sustained benefits across 352 patient-years of exposure, with significant improvements in cardiac function and patient symptoms. Notably, 93% of patients reported improvement in NYHA Functional Class at Week 96.
Aficamten is currently under FDA review with a PDUFA date of December 26, 2025.
Cytokinetics (NASDAQ:CYTK) announced positive Phase 3 results from MAPLE-HCM trial, comparing aficamten to metoprolol in patients with obstructive hypertrophic cardiomyopathy (oHCM). The study demonstrated aficamten's superiority over metoprolol across key metrics.
The trial's primary endpoint showed significant improvement in exercise capacity with aficamten (+1.1 mL/kg/min) compared to metoprolol (-1.2 mL/kg/min), with a difference of 2.3 mL/kg/min (p0.0001)51% of aficamten patients showed improved functional class versus 26% for metoprolol.
Aficamten demonstrated superiority in five of six secondary endpoints, including significant improvements in cardiac biomarkers and patient symptoms. The drug is currently under FDA review with a PDUFA date of December 26, 2025.
Cytokinetics (NASDAQ: CYTK) announced its participation in four major investor conferences during September 2025. The company's management team will engage in fireside chat presentations at the Citi BioPharma Back to School Conference (Sept 2), Wells Fargo Healthcare Conference (Sept 3), Cantor Global Healthcare Conference (Sept 4), and Morgan Stanley Global Healthcare Conference (Sept 9).
All presentations will be accessible via live webcast through Cytokinetics' website, with replays available for 90 days following each event.
Cytokinetics (NASDAQ:CYTK) announced five presentations related to aficamten at the European Society of Cardiology Congress 2025 in Madrid, Spain. The key highlight includes a Hot Line presentation of MAPLE-HCM study results, comparing aficamten versus metoprolol in obstructive HCM patients.
The presentations will feature data from multiple clinical trials including REDWOOD-HCM, SEQUOIA-HCM, and FOREST-HCM, focusing on aficamten's efficacy, safety, and its impact on atrial fibrillation in obstructive hypertrophic cardiomyopathy. The company will host an investor webcast on September 2, 2025 to discuss the MAPLE-HCM results and other presented data.
Cytokinetics (Nasdaq: CYTK) has appointed James M. Daly to its Board of Directors, effective August 19, 2025. Daly brings over 30 years of global biopharmaceutical leadership experience, particularly in commercialization.
Daly most recently served as Chief Commercial Officer at Incyte Corporation, where he led the Jakafi® launch. Previously, he spent 10 years at Amgen in senior leadership roles and 16 years at GlaxoSmithKline. He currently serves on the boards of Madrigal Pharmaceuticals, argenx SE, and Acadia Pharmaceuticals.
Cytokinetics (Nasdaq: CYTK) announced the granting of inducement equity awards to 46 new employees who joined in July and August 2025. The grants include 105,169 stock options at an exercise price of $38.67 per share and 70,879 restricted stock units (RSUs).
The RSUs will vest over 3 years (40% in year 1, 40% in year 2, 20% in year 3), while the stock options will vest over 4 years (25% after year 1, followed by monthly installments). The options have a 10-year term and were granted under Nasdaq Listing Rule 5635(c)(4) as material inducements to employment.
Cytokinetics (NASDAQ:CYTK) reported Q2 2025 financial results and key business updates. The company ended Q2 with ~$1.0 billion in cash and reported a net loss of $134.4 million ($1.12 per share). Total revenues reached $66.8 million, including $52.4 million from the Bayer collaboration agreement.
Key developments include progressing regulatory reviews of aficamten for obstructive HCM, with an FDA PDUFA date of December 26, 2025. The company announced positive topline results from MAPLE-HCM trial and continues advancing multiple Phase 3 clinical trials. Commercial preparations are underway for potential aficamten launch in early 2026.
The company maintained its 2025 guidance with GAAP operating expenses projected between $670-710 million.
Cytokinetics (NASDAQ: CYTK) has scheduled its second quarter 2025 financial results announcement for August 7, 2025 at 4:00 PM ET. Following the earnings release, the company's senior management will host a conference call at 4:30 PM ET to discuss the results and provide business updates.
The conference call will be accessible through a simultaneous webcast from Cytokinetics' Investors & Media section on their website. An archived replay will remain available on the company's website for six months after the event.
Cytokinetics (Nasdaq: CYTK) announced the granting of inducement equity awards to 18 new employees who joined in June and July 2025. The grants include 131,683 stock options at an exercise price of $38.68 per share and 88,755 restricted stock units (RSUs).
The RSUs will vest over 3 years (40% in year 1, 40% in year 2, and 20% in year 3), while the stock options will vest over 4 years (25% after one year, followed by monthly installments). The options have a 10-year term and were granted under Nasdaq Listing Rule 5635(c)(4) as material inducements to employment.